Drug Profile
Lecanemab - BioArctic/Eisai
Alternative Names: Anti-amyloid beta protofibril antibody - Eisai; BAN-2401; Lecanemab-irmb; LEQEMBI; LeqembiLatest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator BioArctic Neuroscience
- Developer BioArctic; Biogen; Eisai Co Ltd
- Class Antidementias; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alzheimer's disease
- Preclinical Brain injuries; Down syndrome